<DOC>
	<DOCNO>NCT00683189</DOCNO>
	<brief_summary>Objectives/Purpose : To determine safety efficacy Vitamin K ( Vit K ) antagonist ( warfarin ) treat Metachromatic Leukodystrophy ( MLD ) .</brief_summary>
	<brief_title>Effect Warfarin Treatment Metachromatic Leukodystrophy</brief_title>
	<detailed_description>Hypothesis : Vit K essential role biosynthesis sulfatides sphingolopids brain . Administering warfarin , Vit K antagonist , may ameliorate phenotype MLD decreasing amount sphingolipid storage neuronal cell . Study Design Prospective : enroll eligible consent subject study . The study include control group family treat physician informed administration drug . 1 . Duration Treatment : 4 week 2 . Pharmacological Intervention : The patient receive warfarin 1.5 mg begin study period . The dosage adjust INR value weekly basis . 3 . Clinical evaluation : The patient undergo clinical assessment prior start treatment end treatment period . The clinical assessment also include administration Gross Motor Function Measure ( GMFM ) , clinical toll evaluation motor development child . 4 . Urine Sulfatide Quantification : Urine sample quantification sulfatide level collect time enrollment , 2 week end treatment period . 5 . Blood Monitoring : The patient undergo blood test PT/INR baseline afterwards , weekly base 4 week . The INR keep safe range 2-2.5 . If INR great 4.0 dosage warfarin lower another blood draw perform 3 day .</detailed_description>
	<mesh_term>Leukodystrophy , Metachromatic</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Children MLD , 1 10 year age receive fail bone marrow transplantation exclude treatment due delay diagnosis reason . Any Children MLD eligible might receive ABMT . Any Children MLD suffer bleed disorder , moderate severe anemia hematological disorder . Any contraindication systemic anticoagulation</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>MLD</keyword>
</DOC>